We used systematic methods to identify relevant studies, apply inclusion and exclusion criteria, evaluate study quality and summarize the diagnostic accuracy of TBNA for mediastinal lymph node involvement in patients with non-small cell lung cancer.
guidelines and systematic reviews. All articles regardless of language were considered for inclusion.
Inclusion and exclusion criteria
The initial search strategy (fig S1A and B) yielded a total of 525 articles (fig 1) . A careful review of titles and abstracts eliminated 398 articles not dealing with TBNA. A hand search of the bibliographies of the remaining 127 articles identified 203 additional potentially relevant studies. We excluded studies that examined rigid bronchoscopy. An initial review of full reports by one investigator (J.E.H.) excluded 268 studies for the following reasons: not a study of staging (n=106); study of rigid bronchoscopy (n=69); review article or no primary data presented (n=61); or miscellaneous reasons (n=32). Sixty-two potentially eligible studies underwent further review (table S1).
Each non-excluded English-language study was reviewed by at least two investigators (J.C.H., M.K.G. or W.G.K.) to assess whether they met inclusion criteria. To be included, a study had to (1) examine TBNA using a flexible bronchoscope for mediastinal staging in patients with known or suspected NSCLC; (2) enroll at least 10 subjects with and/or 10 subjects without mediastinal lymph node involvement; (3) provide sufficient original data to permit calculation of sensitivity and/or specificity; and (4) for studies that did not provide separate data for participants with disorders other than NSCLC, include no more than ten percent (≤10%) of subjects with primary diagnoses other than NSCLC. This final inclusion criteria was chosen because TBNA may be more sensitive in patients with small cell lung cancer, [1] and because staging and treatment differs between NSCLC and small cell lung cancer. [2] [3] These criteria were designed to identify studies that met minimal standards of acceptability. Summary receiver operating characteristic (SROC) curves as described by Moses et al., [88] [89] were constructed to quantitatively summarize the results of studies. These curves demonstrate the trade-off between sensitivity and specificity as the threshold for defining a positive test varies. This method assumes that individual study estimates of sensitivity and specificity represent unique points on a common SROC curve. We performed ordinary least squares regression by using the log odds ratio as the dependent variable and an implied function of the test threshold (logit TPR + logit FPR) as the independent variable, and plotted the relationship between the TPR and FPR after performing a reverse transformation, as we have done previously. [77] [78] Any studies that enrolled no patients with or without mediastinal lymph node involvement were excluded from the SROC analysis.
When the SROC curve is symmetrical (e.g. β≈0), the studies may be summarized by a common LOR. Beta coefficients were not statistically significantly different from zero for tier 1 studies (0.26; 95% CI, -1.75 to 2.28), non-tier 1 studies (-0.28; 95% CI, -1.34 to 0.79) and all studies combined (0.29; 95% CI, -0.13 to 0.70). The LOR represents the odds of a positive test in subjects with disease relative to the odds of a positive test in subjects without disease. To estimate the common log OR, we employed both fixed [84] and random effects models, [84] [85]
adding 0.5 to each cell in any 2 x 2 table that contained one or more zero values.
Pooled sensitivity and specificity were calculated by fixed and random effects models.
When pooling sensitivity and specificity, studies with <10 subjects with or without mediastinal lymph node involvement were excluded, respectively, in the calculations. Heterogeneity was assessed by the Q-statistic. When there was statistically significant heterogeneity, a random effects model, as described by DerSimonian and Laird, [85] was used to summarize trial results. 
Sensitivity analysis
We performed sensitivity analysis to evaluate potential sources of heterogeneity between studies. Sensitivity analysis included stepwise single study elimination to assess significant changes in the LOR or pooled sensitivity. We also assessed whether varying the correction factor from 0.5 to 0.1 had any significant impact on LOR or sensitivity at median specificity on the SROC curve. Finally, we varied assumptions about the definition of a positive or negative biopsy result in certain studies. For example, we reexamined the individual study test results and considered any biopsy specimen negative (when possible) if the biopsy was aborted, if nodal tissue was not located, if there was insufficient tissue for pathologic examination (e.g. inadequate or inconclusive specimens), if the cytopathologist identified the specimen as "contaminated" or if the specimen contained "atypical" cells. All biopsy results that were "suspicious" for malignancy were considered positive as long as the aspirate did not contain an abundance of columnar epithelial cells, if scarce malignant cells were identified or if lymphocytes were absent.
We than reanalyzed the pooled sensitivity, specificity, LOR and kappa-1 coefficient based on these changes and compared this to our base-case analysis (the sensitivity and specificity reported by the study authors).
To date, empirical studies of statistical methods (i.e. funnel plots) in assessing publication bias have focused on randomized clinical control trials of treatment effect and not on diagnostic studies. Thus, there are no universally accepted methods to assess publication bias in trials of diagnostic accuracy. In the absence of any generally accepted method, we constructed inverted funnel plots of standard error versus estimated effect size (LOR) for each individual study to assess for the presence of publication bias. [84] If additional small studies were conducted, but not published due to unfavorable results (e.g. low sensitivity), the funnel plot should be asymmetric.
We also assessed differences in diagnostic accuracy between tier 1 and non-tier 1 studies via discriminant function analysis. [92] This analysis was repeated with respect to studies that confirmed or did not confirm all TBNA results, and studies with high (≥60%) versus low (<60%) prevalence of mediastinal metastasis. P-values were calculated via a parametric Wilks' Lambda test.
Meta-regressions
We performed a multivariate analysis of variance (ANOVA) to examine the effect of specific study characteristics on sensitivity and overall diagnostic accuracy (LOR). [93] [94]
Study characteristics included prevalence of lymph node metastasis (≥60% or <60%) and year of study publication (≥1995 or <1995).
Statistical models
All biostatistical models were programmed in Excel 8. * Highest possible score is 34. † Studies that utilized 'real-time' imaging to guide needle placement had three additional criteria. 5. Was computed tomography (CT) assessment of mediastinal lymphadenopathy appropriate as noted by: -Were significant mediastinal lymph nodes defined as >1 cm in the short axis diameter?
-Was IV contrast used during the scan of the pulmonary hila?
-Was needle placement based on measurements taken from the CT scan?
-Were accessible nodes defined as being within 1 cm or less from the tracheal wall?
-If TBNA was performed blindly (e.g. CT or other imaging study was not performed or results of CT or other imaging study were negative for lymphadenopathy), were TBNA's performed (at a minimum) at the side of the tracheal carina AND/OR regional mediastinum corresponding to the primary tumor?
6. Were TBNA samples collected for BOTH cytological and histological review?
A2. Index test quality -If TBNA was performed using 'real-time' imaging (e.g. CT Fluoroscopy, enbronchial ultrasound or transthoracic ultrasound): -Was the imaging device and procedure used to locate lymph nodes clearly described in detail?
-Was an image obtained to confirm needle position prior to aspiration/biopsy? -Were accessible nodes defined as being within 1 cm or less from the tracheal wall?
B. Reference test quality (by study) 1. Were both positive and negative TBNA staging results compared to a gold standard (a surgical staging procedure with lymph node evaluation/dissection and biopsy/surgical pathologic review)?
2. Was the confirmatory surgical staging procedure clearly described?
C. Application of reference test (by study) 1. Did all patients with a NEGATIVE TBNA undergo a surgical staging procedure with biopsy (e.g. cervical or parasternal mediastinal exploration AND/OR mediastinal exploration at thoracotomy)? 
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